OptiBiotix Health PLC Invited to present at Expoquimia in Barcelona

TIDMOPTI

OptiBiotix Health PLC

07 September 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

OptiBiotix invited to present at Expoquimia in Barcelona

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces it has been invited to present its research and commercial developments at the 18(th) edition of Expoquimia-World Chemical Summit ('Expoquimia') in Barcelona, Spain, on 5 October 2017.

Expoquimia is a multidisciplinary event held triennially in which the industry, professional associations, governments and academia come together to discuss future opportunities and challenges in industrial chemistry and biotechnology. In its previous edition, it had over 600 exhibitors and 38,000 visitors, making it one of the largest industrial chemistry events in Europe.

The Company will present the presentation titled: 'New approaches: microbiome modulation as therapeutic intervention', which will provide an overview of the wide array of existing strategies to modulate the microbiome to support human health, with a special focus on OptiBiotix's technology platforms for the development of novel prebiotics and probiotics.

Stephen O'Hara, CEO of OptiBiotix, commented: "This invitation shows that OptiBiotix is being increasingly regarded as a key player in microbiome science and industrial biotechnology. The interest in our OptiScreen(R) and OptiBiotic(R) platforms suggests that the industry believes we are developing commercially-attractive products that will need to be manufactured at an industrial scale in the near future. We are very excited to take part and feel very honoured and thankful to the organisers for considering us."

 
 OptiBiotix Health plc                                            www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                         Contact via 
                                                                      Walbrook below 
 
 Walbrook PR Ltd                    Tel: [phone] or [e-mail] 
 Anna Dunphy                                                              Mob: 07876 
                                                                             741 001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAOKADQPBKDACK

(END) Dow Jones Newswires

September 07, 2017 02:01 ET (06:01 GMT)